A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

May 31, 2013

Conditions
Oral Mucositis
Interventions
DEVICE

MuGard

Mucoadhesive Oral Wound Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day

DEVICE

Control Rinse

Aqueous Control Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day.

Trial Locations (18)

12601

Vassar Brothers Medical Center, Poughkeepsie

14215

VA Western New York Health System, Buffalo

15212

Allegheny General Hospital, Pittsburgh

15232

University of Pittsburgh Medical Center, Pittsburgh

27834

21st Century Oncology- Carolina Radiation Medicine, Greenville

28054

CaroMont Health Comprehensive Cancer Center, Gastonia

31904

John B. Amos Cancer Center, Columbus

32806

MD Anderson Cancer Center Orlando, Orlando

53211

Columbia St. Mary's Hospital, Milwaukee

68106

Missouri Valley Cancer Consortium, Omaha

71913

St. Joseph's Mercy Cancer Center- Hot Springs Radiation Oncology, Hot Springs

85206

Ironwood Cancer and Research Centers, Mesa

85251

21st Century Oncology TRC Headquarters, Scottsdale

94520

John Muir Medical Center, Concord

95926

Enloe Medical Center- Cancer Center, Chico

98201

Providence Hospital - Pacific Campus; Flynn Cancer Center, Everett

98225

PeaceHealth St. Joseph Cancer Center, Bellingham

02302

Signature Healthcare Brockton Hospital, Brockton

Sponsors
All Listed Sponsors
lead

Access Pharmaceuticals, Inc.

INDUSTRY

NCT01283906 - A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients | Biotech Hunter | Biotech Hunter